These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25547388)

  • 1. The biology of castration-resistant prostate cancer.
    Lian F; Sharma NV; Moran JD; Moreno CS
    Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
    Sharp A; Welti J; Blagg J; de Bono JS
    Clin Cancer Res; 2016 Sep; 22(17):4280-2. PubMed ID: 27330057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galeterone activity in castration-resistant prostate cancer.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
    [No Abstract]   [Full Text] [Related]  

  • 5. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
    Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
    Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on systemic therapy for advance prostate cancer.
    Carthon B; Rossi PJ
    Curr Probl Cancer; 2015; 39(1):52-62. PubMed ID: 25637932
    [No Abstract]   [Full Text] [Related]  

  • 8. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.
    Roviello G; Sigala S; Sandhu S; Bonetta A; Cappelletti MR; Zanotti L; Bottini A; Sternberg CN; Fox SB; Generali D
    Eur J Cancer; 2016 Jul; 61():111-21. PubMed ID: 27162152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sequential therapy for castration-resistant prostate cancer].
    Nozawa M; Uemura H
    Nihon Rinsho; 2016 May; 74 Suppl 3():644-8. PubMed ID: 27344809
    [No Abstract]   [Full Text] [Related]  

  • 13. Current treatment of non-metastatic castration-refractory prostate cancer.
    Büchler T
    Klin Onkol; 2021; 34(3):185-191. PubMed ID: 34362254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.
    Martinez-Ariza G; Hulme C
    Pharm Pat Anal; 2015; 4(5):387-402. PubMed ID: 26389532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer.
    Blas L; Shiota M
    Curr Cancer Drug Targets; 2023; 23(6):428-432. PubMed ID: 36803751
    [No Abstract]   [Full Text] [Related]  

  • 17. [Not Available].
    Bernemann C; Bögemann M; Steinestel J; Schrader AJ
    Oncol Res Treat; 2017; 40 Suppl 2():8-10. PubMed ID: 28365708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer: AR-V7 status in CTCs is a treatment-specific biomarker.
    Stone L
    Nat Rev Urol; 2016 Aug; 13(8):433. PubMed ID: 27349368
    [No Abstract]   [Full Text] [Related]  

  • 19. PARP inhibition in castration-resistant prostate cancer.
    Nappi L; Gleave ME
    Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
    [No Abstract]   [Full Text] [Related]  

  • 20. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.